A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity

Obesity Research

Volumn 11, Issue 6, 2003, Pages 722-733

  Bray, George A ^a   Hollander, Priscilla ^b   Klein, Samuel ^c   Kushner, Robert ^d   Levy, Brian ^e   Fitchet, Martin ^e   Perry, Barbara H ^e  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^b Heart Hospital Baylor   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Central nervous system; Multicenter clinical trial; Peripheral nervous system; Side effects; Weight loss drugs

Indexed keywords

EID: 0346593400     PISSN: 10717323     EISSN: None     Source Type: Journal    
DOI: 10.1038/oby.2003.102     Document Type: Article

References (34)

1. World Health Organization. Obesity: Preventing and Managing the Global Epidemic. WHO Technical Series Report 894. Geneva, Switzerland: World Health Organization; 2000.
2. NHLBI Obesity Initiative Task Force. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - the evidence report. Obes Res. 1998; 9(Suppl 2):51S-209S.
3. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA. 2002;288:1723-7.
4. Bray GA. Obesity: a time bomb to be defused. Lancet. 1988;352:160-1.
5. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21:1414-31.
6. Thomas PR, ed. Weighing the Options: Criteria for Evaluating Weight-Management Programs. Washington, DC: National Academy Press; 1995.
7. Bray GA, Blackburn GL, Ferguson JM, et al. Sibutramine produces dose-related weight loss. Obes Res. 1999;7:189-98.
8. Sjöström L, Rissanen A, Andersen T, et al., for the European Multicentre Orlistat Study Group. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet. 1998; 352:167-72.
9. York DA, Singer L, Thomas S, Bray GA. Effect of topiramate on body weight and body composition of OsborneMendel rats fed a high-fat diet: alterations in hormones, neuropeptide, and uncoupling-protein mRNAs. Nutrition. 2000; 16:967-75.
10. Richard D, Picard F, Lemieux C, Lalonde J, Samson P, Deshaies Y. The effects of topiramate and sex hormones on energy balance of male and female rats. Int J Obes Relat Metab Disord. 2002;26:344-53.
11. Reife R, Pledger G, Wu SC. Topiramate as add-on therapy: pooled analysis of randomized controlled trials in adults. Epilepsia. 2000;41(Suppl 1):S66-S71.
12. Rosenfeld WE. Topiramate: a review of preclinical, pharmacokinetic, and clinical data. Clin Ther. 1997;19:1294-308.
13. McElroy SL, Suppes T, Keck PE Jr, et al. Open-label adjunctive topiramate in the treatment of bipolar disorders. Biol Psychiatry. 2000;47:1025-33.
14. Shapira NA, Goldsmith TD, McElroy SL. Treatment of binge-eating disorder with topiramate: a clinical case series. J Clin Psychiatry. 2000;61:368-72.
15. World Medical Association. Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June, 1964, and amended by the 48th WMA General Assembly, Somerset West, Republic of South Africa, October, 1996.
16. Dunnett CW, Tamhane AC. Step-down multiple tests for comparing treatments with a control in unbalanced one-way layouts. Stat Med. 1991;10:939-47.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Slat Assoc. 1958;53:457-81.
18. Rogawski MA, Porter RJ. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol Rev. 1990;42:223-86.
19. Macdonald RL, McLean MJ. Anticonvulsant drugs: mechanisms of action. Adv Neurol. 1986;44:713-36.
20. Munro JF, MacCuish AC, Wilson EM, Duncan LJP. Comparison of continuous and intermittent anorectic therapy in obesity. Br Med J. 1968;1:352-4.
21. Guy-Grand B, Apfelbaum M, Crepaldi G, Gries A, Lefebvre P, Turner P. International trial of long-term dexfenfluramine in obesity. Lancet. 1989;2:1142-5.
22. Weintraub JM, Sundaresan PR, Madan M, et al. Long-term weight control study I (weeks 0 to 34): the enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo. Clin Pharmacol Ther. 1992;51:586-94.
23. Wirth A, Krause J. Long-term weight loss with sibutramine: a randomized controlled trial. JAMA. 2001;286:1331-9.
24. Rössner S, Sjöström L, Noack R, Meinders AE, Noseda G, for the European Orlistat Obesity Study Group. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. Obes Res. 2000;8:49-61.
25. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA. 1999;281:235-42.
26. Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR, for the Orlistat Primary Care Study Group. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med. 2000-9:160-7.
27. Bray GA, Greenway FL. Current and potential drugs for treatment of obesity. Endocr Rev. 1999;20:805-75.
28. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord. 1992;16:397-415.
29. Tuomilehto J, Lindstrom J, Eriksson JG, et al., for the Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-50.
30. The Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
31. Cutler JA. Randomized clinical trials of weight reduction in nonhypertensive persons. Ann Epidemiol. 1991;1:363-70.
32. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr. 1992;56:320-8.
33. O'Connor HT, Richman RM, Steinbeck KS, Caterson ID. Dexfenfluramine treatment of obesity: a double blind trial with post trial follow-up. Int J Obes Relat Metab Disord. 1995;19:181-9.
34. Van Gaal LF, Broom JI, Enzi G, Toplak H for the Orlistat Dose-Ranging Study Group. Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Eur J Clin Pharmacol. 1998;54:125-32.